The Danish drugmaker Novo Nordisk has officially launched its weight loss pill, Wegovy, in the United States as of March 15, 2024. The medication, which is...
Health Canada is currently reviewing nine submissions for generic versions of popular obesity medications, potentially paving the way for lower prices this summer. The focus is...
The oral medication Wegovy, designed for weight loss in adults, may soon be available in Canada pending approval from Health Canada. This announcement follows the recent...
Eli Lilly is positioning itself for sustained growth in the pharmaceutical sector by capitalizing on its leading role in diabetes and obesity treatments. The company is...
Negotiations to include the weight-loss drug Wegovy under Canadian public health plans have collapsed as Novo Nordisk, the Danish manufacturer, declined to pursue discussions. This development...
U.S. stock markets experienced a substantial rally during the week ending November 24, 2023, buoyed by strong performances from major healthcare companies, including Sanofi, Eli Lilly,...
U.S. stock markets experienced a notable rally during the trading week ending November 24, 2023, buoyed by strong performances from major healthcare companies such as Sanofi,...
Novo Nordisk announced on March 4, 2024, that its clinical trials for an oral version of the Alzheimer’s drug semaglutide did not succeed in slowing the...
Novo Nordisk has announced significant price reductions for its obesity treatments, Wegovy and Ozempic, in an effort to compete more effectively against rival Eli Lilly, which...
Novo Nordisk has announced a significant price reduction for its weight-loss injection, Wegovy, by up to 37% in India. This strategic decision comes as the Danish...
